Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (formally HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Melbourne, Victoria 3086, Au
- Phone
- +61 1300 554 474
- re****@****.com.au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- hexima.com.au
- HQ
- Melbourne, Victoria
Hexima Limited (Asx:hxl) Questions
Hexima Limited (Asx:Hxl)'s helpline number is +61 1300 554 474
Hexima Limited (Asx:Hxl)'s website is hexima.com.au
Hexima Limited (Asx:Hxl)'s LinkedIn profile is https://au.linkedin.com/company/hexima-limited
Hexima Limited (Asx:Hxl) has
7 employees.
View email and phone details for 7
employees at Hexima Limited (Asx:Hxl).
Hexima Limited (Asx:Hxl)'s industry is
Biotechnology Research
Hexima Limited (Asx:Hxl)'s top competitors are
Ausbiotech,
Bioscience Managers,
Csiro,
Arovella Therapeutics Asx: Ala,
Aquila Black,
Incannex Healthcare Inc,
Flora Victoria,
Intrinsic Investment Management,
Bioinvest - Aust. Online Biotech & Medical Community,
Radiopharm Theranostics.
Hexima Limited (Asx:Hxl)'s support email address is registrars@linkmarketservices.com.au
Hexima Limited (Asx:Hxl)'s categories are Biotechnology Research
Hexima Limited (Asx:Hxl)'s founding year is 1998
